While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.
Aug 17, 2011
0
0
A new prognostic tool predicts how long someone diagnosed with chronic lymphocytic leukemia (CLL) will be able to wait before starting cancer treatment. Researchers describe what they hope will become a point-of-care resource ...
Apr 8, 2020
0
33
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could help overcome treatment ...
Feb 1, 2024
0
8
A 20-year study following 110,645 workers who helped clean up after the 1986 Chernobyl nuclear power plant accident in the former Soviet territory of Ukraine shows that the workers share a significant increased risk of developing ...
Nov 8, 2012
0
0
(HealthDay)—A new T-cell immunotherapy has led to sustained regression in many previously relapsing and treatment-resistant cases of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, ...
Feb 17, 2016
0
5
A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which will be published January ...
Jan 4, 2018
0
6
Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study published in Blood Advances.
Feb 5, 2024
0
0
Clinical results published in the OnLine First edition of New England Journal of Medicine show that the new drug acalabrutinib (ACP-196) promotes high response rates that are durable in patients with chronic lymphocytic leukemia ...
Dec 7, 2015
0
2
A new study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) helps confirm that a molecule targeted ...
Dec 19, 2013
0
0
Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained. To develop the drug, ...
Mar 13, 2015
0
8
